Treatment compliance among adult cervical cancer patients receiving care at Uganda cancer institute, Uganda: a retrospective data review.
Cervical cancer
Treatment compliance
Uganda
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
05 Jul 2023
05 Jul 2023
Historique:
received:
16
11
2022
accepted:
02
07
2023
medline:
7
7
2023
pubmed:
6
7
2023
entrez:
5
7
2023
Statut:
epublish
Résumé
Cervical cancer is one of the most common cancers and a major cause of morbidity among women globally. Chemoradiation therapy is the preferred standard treatment for women with stage IB to IVA. However, the benefits of this treatment can only be achieved if patients adhere to the treatment guidelines. In this study, the proportion of compliance or adherence to chemo-radiation treatment among cervical cancer patients at Uganda Cancer Institute (UCI) was determined. This was a cross-sectional study that reviewed data retrospectively for 196 cervical cancer patients who were prescribed to chemo-radiation therapy at UCI between November 2020 to May 2021, having been diagnosed with disease stage IB to IVA. Patient data and information on treatment uptake was obtained by review of the patient's medical records. Treatment compliance was determined by calculating the number of participants who completed the prescribed treatment (definitive pelvic concurrent chemoradiation to 50 Gy external beam radiotherapy with weekly concurrent cisplatin followed by intracavitary brachytherapy 24 Gy in 3 fractions at 8 Gy once a week over 3 weeks). Associations between patient factors and treatment adherence were determined using logistic regression analysis. In all statistical tests, a P- value of < 0.05 was considered as significant. The proportion of patients who were administered with external beam radiation (EBRT), chemotherapy and brachytherapy were 82.6%, 52.04% and 66.2% respectively. However, only 23 of 196 patients (11.7%) were found to have adhered to the treatment plan by completion of all definitive pelvic concurrent chemoradiation to 50 Gy external beam radiotherapy (5 weeks) with weekly concurrent cisplatin (5 cycles) followed by intracavitary brachytherapy 24 Gy in 3 fractions at 8 Gy once a week over 3 weeks (3 sessions). There were no significant associations between patient factors and treatment adherence after multivariable analysis. Treatment compliance was found in only 12% of the cohort participants. No association of patient factors with treatment compliance was found. Additional studies on treatment adherence with larger sample sizes are needed to confirm the associations.
Sections du résumé
BACKGROUND
BACKGROUND
Cervical cancer is one of the most common cancers and a major cause of morbidity among women globally. Chemoradiation therapy is the preferred standard treatment for women with stage IB to IVA. However, the benefits of this treatment can only be achieved if patients adhere to the treatment guidelines. In this study, the proportion of compliance or adherence to chemo-radiation treatment among cervical cancer patients at Uganda Cancer Institute (UCI) was determined.
METHODS
METHODS
This was a cross-sectional study that reviewed data retrospectively for 196 cervical cancer patients who were prescribed to chemo-radiation therapy at UCI between November 2020 to May 2021, having been diagnosed with disease stage IB to IVA. Patient data and information on treatment uptake was obtained by review of the patient's medical records. Treatment compliance was determined by calculating the number of participants who completed the prescribed treatment (definitive pelvic concurrent chemoradiation to 50 Gy external beam radiotherapy with weekly concurrent cisplatin followed by intracavitary brachytherapy 24 Gy in 3 fractions at 8 Gy once a week over 3 weeks). Associations between patient factors and treatment adherence were determined using logistic regression analysis. In all statistical tests, a P- value of < 0.05 was considered as significant.
RESULTS
RESULTS
The proportion of patients who were administered with external beam radiation (EBRT), chemotherapy and brachytherapy were 82.6%, 52.04% and 66.2% respectively. However, only 23 of 196 patients (11.7%) were found to have adhered to the treatment plan by completion of all definitive pelvic concurrent chemoradiation to 50 Gy external beam radiotherapy (5 weeks) with weekly concurrent cisplatin (5 cycles) followed by intracavitary brachytherapy 24 Gy in 3 fractions at 8 Gy once a week over 3 weeks (3 sessions). There were no significant associations between patient factors and treatment adherence after multivariable analysis.
CONCLUSIONS
CONCLUSIONS
Treatment compliance was found in only 12% of the cohort participants. No association of patient factors with treatment compliance was found. Additional studies on treatment adherence with larger sample sizes are needed to confirm the associations.
Identifiants
pubmed: 37407972
doi: 10.1186/s12885-023-11145-1
pii: 10.1186/s12885-023-11145-1
pmc: PMC10324123
doi:
Substances chimiques
Cisplatin
Q20Q21Q62J
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
631Informations de copyright
© 2023. The Author(s).
Références
Asia Pac J Clin Oncol. 2017 Oct;13(5):e373-e380
pubmed: 27726297
Oncologist. 2018 Sep;23(9):1024-1032
pubmed: 29567823
Afr Health Sci. 2022 Mar;22(1):327-337
pubmed: 36032470
JCO Oncol Pract. 2021 Dec;17(12):e1958-e1967
pubmed: 34550749
J Pak Med Assoc. 2006 Oct;56(10):436-40
pubmed: 17144388
Risk Manag Healthc Policy. 2014 Feb 20;7:35-44
pubmed: 24591853
Gynecol Oncol Rep. 2017 Feb 03;20:37-40
pubmed: 28275695
AIDS. 2018 Jan 14;32(2):171-177
pubmed: 29028665
Int J Womens Health. 2014 Jan 24;6:123-30
pubmed: 24493933
Clin Med Insights Oncol. 2013 Jun 27;7:151-8
pubmed: 23843724
PLoS One. 2022 Sep 21;17(9):e0274884
pubmed: 36129898
J Clin Oncol. 2016 Sep 20;34(27):3354-5
pubmed: 27382101
Cancer Manag Res. 2020 Dec 09;12:12649-12655
pubmed: 33328762
J Glob Oncol. 2018 Dec;4:1-11
pubmed: 30582433
Gynecol Oncol Res Pract. 2017 Oct 18;4:15
pubmed: 29075505
Obstet Gynecol. 2018 May;131(5):899-908
pubmed: 29630020
Ann Glob Health. 2020 Sep 14;86(1):117
pubmed: 32983913
BMJ Open. 2022 Mar 16;12(3):e056722
pubmed: 35296484
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Indian J Palliat Care. 2013 Sep;19(3):158-65
pubmed: 24347906
J Cancer Policy. 2021 Mar;27:100263
pubmed: 35559936
Value Health. 2008 Jan-Feb;11(1):44-7
pubmed: 18237359
Gynecol Oncol Rep. 2017 Sep 01;22:16-20
pubmed: 28948205
J Glob Oncol. 2019 May;5:1-5
pubmed: 31067142